Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anesta OT-nicotine oral transmucosal smoking cessation product to enter Phase III studies.

This article was originally published in The Tan Sheet

Executive Summary

ANESTA OT-NICOTINE ORAL TRANSMUCOSAL SMOKING CESSATION PRODUCT will enter Phase III clinical trials once the Salt Lake City, Utah-based manufacturer of oral transmucosal delivery drug systems meets with FDA to determine protocol particulars, Anesta said June 17. The company hopes ultimately to market the product OTC although it is not ruling out initial availability as a prescription drug. Anesta presented Phase II trial results on June 14 at the annual Society for Research on Tobacco and Nicotine meeting in Nashville, Tenn. The Phase II efficacy trial compared OT-nicotine to a nicotine transdermal patch and nicotine polacrilex gum.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel